MARKET

LLY

LLY

Lilly Eli & Co
NYSE

Real-time Quotes | Nasdaq Last Sale

305.96
+3.36
+1.11%
After Hours: 306.36 +0.4 +0.13% 17:20 05/24 EDT
OPEN
303.71
PREV CLOSE
302.60
HIGH
307.67
LOW
299.80
VOLUME
2.80M
TURNOVER
0
52 WEEK HIGH
314.00
52 WEEK LOW
193.95
MARKET CAP
290.71B
P/E (TTM)
45.40
1D
5D
1M
3M
1Y
5Y
Top Healthcare Stocks for June 2022
These are the healthcare stocks with the best value, fastest growth, and most momentum for June 2022.
Investopedia · 11h ago
Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting
Benzinga · 11h ago
Dow Jones Falls As Snap Plunges 39% On Profit Warning
The Dow Jones Industrial Average dropped Tuesday, as Snap stock plunged 39% after issuing a profit and sales warning for the second quarter.
Investor's Business Daily · 15h ago
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Zacks · 15h ago
COVID-19 sales boom for vaccine and drug makers might be over - analysts
As the demand dries up and the pandemic evolves, Wall Street projects the sales for COVID-19 vaccines and therapeutics to plateau amid ample supplies while companies continue to assess the
Seekingalpha · 15h ago
Lilly mirikizumab helps reduce ulcerative colitis symptoms in 50% patients at 1 year in trial
Eli Lilly (NYSE:LLY) said ~50% of patients with ulcerative colitis (UC) treated with mirikizumab achieved clinical remission at one year, compared to placebo in a late-stage study. The Indianapolis-based pharma
Seekingalpha · 19h ago
BRIEF-Eli Lilly Says 50% With Ulcerative Colitis Treated With Mirikizumab Achieved Clinical Remission At One Year
reuters.com · 21h ago
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks achieved and maintained statistically superior and clinically meaningful improvements at one year compared...
PR Newswire · 21h ago
More
No Data
Learn about the latest financial forecast of LLY. Analyze the recent business situations of Lilly Eli & Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

23.08%Strong Buy
42.31%Buy
30.77%Hold
3.85%Under-perform
0.00%Sell
Analyst Price Target
The average LLY stock price target is 318.13 with a high estimate of 369.00 and a low estimate of 260.00.
High369.00
Average318.13
Low260.00
Current 305.96
EPS
Actual
Estimate
0.661.311.972.62
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 2.73K
Institutional Holdings: 844.90M
% Owned: 88.92%
Shares Outstanding: 950.16M
TypeInstitutionsShares
Increased
837
22.56M
New
328
2.66M
Decreased
673
26.51M
Sold Out
85
1.58M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Ricks
Chief Financial Officer/Senior Vice President
Anat Ashkenazi
Senior Vice President/Chief Information Officer
Diogo Rau
Senior Vice President/Chief Scientific Officer
Daniel Skovronsky
Senior Vice President/Chief Compliance Officer
Alonzo Weems
Senior Vice President/General Counsel/Secretary
Anat Hakim
Senior Vice President/Director of Human Resources
Stephen Fry
Senior Vice President
Edgardo Hernandez
Senior Vice President
Patrik Jonsson
Senior Vice President
Michael Mason
Senior Vice President
Johna Norton
Senior Vice President
Leigh Pusey
Senior Vice President
Jacob Van Naarden
Senior Vice President
Anne White
Senior Vice President
Ilya Yuffa
Lead Director/Independent Director
Juan Luciano
Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
J. Erik Fyrwald
Independent Director
Mary Hedley
Independent Director
Jamere Jackson
Independent Director
Kimberly Johnson
Independent Director
William Kaelin
Independent Director
Marschall Runge
Independent Director
Gabrielle Sulzberger
Independent Director
Jackson Tai
Independent Director
Karen Walker
No Data
No Data
About LLY
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Webull offers kinds of Eli Lilly And Co stock information, including NYSE:LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.